

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: Canntab Therapeutics Limited (the "Issuer").

Trading Symbol: PILL

Number of Outstanding Listed Securities: 33,067,124

Date: September 30, 2020

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

*On September 21, 2020 the Issuer announced that, pursuant to a filing made in March 2017, the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,772,837 to Canntab, titled "Modified Release Multi-Layer Tablet Cannabinoid Formulations. The term of the patent expires on March 15, 2038.*

*Larry Latowsky, CEO of Canntab said "this is a major milestone that confirms our proprietary formulations are unique and differentiated from other product offerings in the global marketplace which will support a faster revenue stream as we begin production and distribution in the immediate future. This is the first patent that was issued to date out of the 13 that we have applied for and will be leveraged to solidify Canntab's position as the leader in solid dose (hard pill) formulations of medicinal cannabinoids.*

*The patent granted is for Canntab's bi-layer or multi-layer tablets consisting of both Instant Release ("IR") and Extended Release ("XR") formulations with THC, CBD and a variety of Terpenes and other Cannabinoids found in full spectrum Cannabis and Hemp oil resin.*

*Canntab believes that its hard pill formulations are superior to all other CBD and THC delivery systems since they are true pharmaceutical grade delivery systems which provide for superior ingredient stability, enhanced bioavailability, and provide customizable and precise dosing. Canntab believes and intends to prove greater bioavailability through a blood level study at a 3rd party Clinical Research Organization (CRO). In addition, whether it is for medical, recreational or nutraceutical purposes, Canntab is able to provide extended release formulations making it the clear delivery choice for doctors, patients or the average consumer.*

*"Canntab expects this and future patents to be very valuable in the development of our strategic partnerships and alliances and in our efforts to secure worldwide distribution of our proprietary products. As the medical community continues to recognize Cannabinoid alternatives to traditional therapies, we will continue to develop innovative approaches to support many clinical applications" continued Latowsky.*

*In addition, Canntab is conducting research to confirm its belief that its combined CBD and THC tablet can be effective to treat nicotine, alcohol, cannabis, opioid and other forms of addiction. Canntab will be using a derivative of these formulations for its clinical trial with Dr. Donald Garbuz from the University of British Columbia and as previously released in December 2018. This study aims to demonstrate the potential for the reduction or elimination of the use of opiates in patients during post-operative pain management.*

*This issued patent covers Canntab's modified release pharmaceutical compositions and more specifically compositions comprising cannabinoids and a process for preparation thereof as well as methods for administering the compositions to human users. The compositions may contain a combination of ingredients in proportions calculated to achieve therapeutic effect.*

*Canntab has filed applications for 13 patents in Canada and the United States that cover a range of processes and formulations that it uses to create its precision oral-delivery hard tablets, the future of medical cannabis. These patents include Canntab's proprietary nano-emulsification technology, granulation process, methods of manufacturing and covers its full line of precision oral-delivery hard tablets including instant (immediate) release tablets, extended release tablets, oral dissolvable tablets. Canntab has also filed a patent for an exclusive formulation of THC and CBD for the treatment of opioid addiction treatment therapy.*

*On September 28, 2020 the Issuer filed its Audited Financial Statements for the year ended May 31, 2020 along with its Management Discussion and Analysis for the same period.*

2. Provide a general overview and discussion of the activities of management.

*None other than as described above.*

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

*N/A*

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

*N/A*

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

*N/A.*

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

*N/A*

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

*N/A*

8. Describe the acquisition of new customers or loss of customers.  
N/A
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.  
  
*See Section One – “Report on Business”.*
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.  
N/A.
11. Report on any labour disputes and resolutions of those disputes if applicable.  
N/A
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.  
N/A
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.  
N/A
14. Provide details of any securities issued and options or warrants granted.  
N/A
15. Provide details of any loans to or by Related Persons.  
N/A
16. Provide details of any changes in directors, officers or committee members.  
N/A
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.  
  
N/A

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer, which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated October 6, 2020.

Richard Goldstein  
Name of Director or Senior  
Officer

signed "Richard Goldstein"  
Signature

Chief Financial Officer  
Official Capacity

<b><i>Issuer Details</i></b> Name of Issuer Canntab Therapeutics Limited.	For Month End September, 2020	Date of Report YY/MM/DD 20/10/06
Issuer Address 1 Adelaide Street East		
City/Province/Postal Code Toronto, ON M5C 2V9	Issuer Fax No. ( )	Issuer Telephone No. 416-957-6303
Contact Name Richard Goldstein	Contact Position CFO	Contact Telephone No. 416-957-6303
Contact Email Address richard@canntab.ca	Web Site Address www.canntab.ca	